Scholar Rock (NASDAQ: SRRK)
Scholar Rock Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Scholar Rock Company Info
Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The firm offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
News & Analysis
Here's Why Everybody's Talking About Scholar Rock Right Now
Successful clinical-trial results recently made Scholar Rock one of the stock market's top performers.
Why Scholar Rock Holding Stock Soared Today
The market celebrated Scholar Rock's upsized stock offering and plans to advance development of a new obesity treatment. Here's what investors need to know.
Why Scholar Rock Stock Flew High Today
A venture capital group significantly increased its stake in the company.
3 Beaten-Down Biotech Stocks: Can They Recover?
These drugmaker stocks may have been hammered down to bargain-bin prices.
2 Top Biotech Stocks From the IPO Class of 2018 to Buy Now
Compelling clinical trial results so far make these biotech stocks worth more attention than they've received so far.
Why Scholar Rock Stock Is Skyrocketing Today
Investors are fired up about the company's interim phase 2 results for an experimental spinal muscular atrophy drug.
Why Carnival, Steelcase, and Scholar Rock Holding Slumped Today
Find out why these stocks missed the rally.
Why Scholar Rock Is Sinking Today
The good news? The reason behind the drop should only be a temporary issue.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.